NSE: SAILIFE · 9 November 2026
- Sai Life Sciences has risen 15.21% over 2 trading sessions; today's move is +5.32%.
- Sai Life Sciences released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Quarterly operational revenue grew by 23% year-on-year to ₹659 crore, while EBITDA reached ₹187 crore with a margin of 28%. For the half year, revenue stood at ₹1,213 crore with total capex incurred at ₹621 crore.
- Trading volume was 9.06 times the 20-day average daily volume.
Sai Life Sciences share price: 15.21% rise over 2 trading sessions
Sai Life Sciences Ltd. shares rose 5.32% on Monday, trading between an intraday low of ₹1,699.00 and a high of ₹1,897.30 to close at ₹1,836.80.
The broader market showed muted movement as the Nifty edged up by 0.06%, whereas the sector benchmark Nifty Pharma recorded a strong gain of 3.42%. Sai Life Sciences outperformed both indices significantly, building on strong recent momentum that includes a 5-day return of 19.11% and a 20-day return of 23.46%.
1.01 crore shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 11.17 lakh shares (9.06 times). The five-day average daily volume was 30.26 lakh shares. Separately, the NSE report for 9 November 2026 showed 14.45 lakh shares delivered, representing 14.27% of that day’s traded volume. The same report recorded 415,733 trades.
The stock's 5.32% rally accompanied by exceptionally high volume (9.06 times the 20-day average volume) aligns with ongoing market absorption of last week's solid Q2 FY27 earnings report and strong performance in the broader Nifty Pharma sector.
Latest Company Developments
Sai Life Sciences released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Quarterly operational revenue grew by 23% year-on-year to ₹659 crore, while EBITDA reached ₹187 crore with a margin of 28%. For the half year, revenue stood at ₹1,213 crore with total capex incurred at ₹621 crore.
Demonstrates robust core business expansion across both CRO and CDMO segments, supporting management's outlook for a stronger second half.
The Board of Directors approved the appointment of Mr. Sidhartha Das as Senior Vice President & Head of Human Resources, Mr. Vijay Kumar Suthari as Vice President & Head of Quality and Regulatory Affairs, and Mr. Gopalakrishnan Sriram as Senior Vice President of Corporate Communications. All appointments became effective November 5, 2026.
Reinforces leadership depth across key operational, quality compliance, and human capital functions during a phase of rapid corporate growth.
a press release dated November 05, 2026, titled "Press Release on Financial Results ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.56% on 30 September 2026. This compares with 29.47% on 30 June 2026, a change of +0.09 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
Maintained a positive stance on the company's integrated CRDMO growth model and order pipeline.
Designated Sai Life Sciences as a top CRDMO pick, outlining multiple structural growth drivers.
Historical Bulk / Block Deals
What to Watch Next
- Execution of ongoing capacity and capability expansion programs backed by H1 FY27 capex of ₹621 crore
- CDMO and CRO revenue mix stability in upcoming quarters
- Sustained delivery volumes relative to the 20-day average volume of ~11.17 lakh shares
- Management commentary and updates regarding order inflows from global pharmaceutical partners
Other Dated Coverage
- Sai Life Sciences Share Price Today: Rises 15.46% in 2 Trading Sessions | 6 November 2026 — 6 November 2026
- Sai Life Sciences Share Price Today: Why SAILIFE Is Rising 1.03% | 3 November 2026 — 3 November 2026
- Sai Life Sciences Share Price Today: Why SAILIFE Is Falling 0.98% | 2 November 2026 — 2 November 2026
More Sai Life Sciences news and dated analysis →
Frequently Asked Questions
What is the latest Sai Life Sciences company news?
Sai Life Sciences released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Quarterly operational revenue grew by 23% year-on-year to ₹659 crore, while EBITDA reached ₹187 crore with a margin of 28%. For the half year, revenue stood at ₹1,213 crore with total capex incurred at ₹621 crore.
How strong was Sai Life Sciences’s trading volume?
1.01 crore shares traded, 9.06 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.